in

Pfizer dosing first patient in phase 2/3 trial of daily COVID pills

by Tyler Durden

Pfizer revealed Wednesday that it has finally dosed its first patient participating in a Phase 2/3 study to examine the effectiveness of PF-07321332, an oral antiviral designed to combat COVID-19.

The randomized, double-blind trial will enroll approximately 1,140 participants, who will receive PF07321332/ritonavir, or placebo, orally every 12 hours for five days.

Pfizer CEO Albert Burla weighed in via a tweet:

This medication is designed for patients who have not been hospitalized, who have symptoms of COVID but have a low risk of seeing them develop severe disease. Currently, there are no officially approved COVID treatments, and that’s a fact Podcast host Joe Rogan hinted in a video where he revealed his diagnosis with COVID.

According to Pfizer’s press release, PF-07321332 is a protease inhibitor, meaning that it blocks the activity of a key protease enzyme required by SARS-CoV-2 for replication.

This study is just one part of a development program that includes studies around the world where authorities are evaluating whether the drug is suitable for use in a wide population.

Even those who have been vaccinated still need treatments because, as the public has learned, vaccines are not as effective as initially thought. Therefore, treatment will always be needed to prevent the spread of mild to moderate COVID-19.

Given the huge need for a COVID treatment, and Pfizer’s optimism about the drug, the company has already started producing the drug even though it hasn’t finished clinical trials.

Sure enough, when it comes to curing COVID, the world has been disappointed once already. Gilead’s Remdesivir has proven to be much less effective than some had expected.

Source: ZeroHedge


What do you think?

Written by Joseph

Leave a Reply

Your email address will not be published.

Austin stream on understanding the science of strength training

Can CBD Oil Help With Anxiety